Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00003401 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-10-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma that has been treated for longer than 12 months.

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: carmustine
DRUG: cisplatin
DRUG: cyclophosphamide
DRUG: dexamethasone
DRUG: etoposide
DRUG: gemcitabine hydrochloride
DRUG: melphalan
DRUG: paclitaxel
PROCEDURE: bone marrow ablation with stem cell support
PROCEDURE: peripheral blood stem cell transplantation

Sponsors & Collaborators

University of Maryland, Baltimore
lead OTHER

Principal Investigators

Barry R. Meisenberg, MD · University of Maryland Greenebaum Cancer Center

Study Design

Purpose: TREATMENT

Eligibility

Min Age: 18 Years
Max Age: 70 Years
Sex: ALL
Healthy Volunteers: No

Timeline & Regulatory

Start: 1999-01-31
Primary Completion: 2002-09-30
Completion: 2002-09-30

Countries

United States

Study Locations

More Related Trials

Entities

Drugs